Lista de obras - Guillaume Cartron - Dominio Público Uruguay

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

artículo científico publicado en 2015

An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma

scientific article published on 01 August 2018

Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas

artículo científico publicado en 2017

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

artículo científico publicado en 2013

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study

artículo científico publicado en 2016

CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity.

artículo científico publicado en 2016

CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia.

artículo científico publicado en 2006

Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis

artículo científico publicado en 2014

Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia

artículo científico publicado en 2010

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.

artículo científico publicado en 2016

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

artículo científico publicado en 2012

Clinical radioimmunotherapy--the role of radiobiology.

artículo científico publicado en 2011

Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant

artículo científico publicado en 2013

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

artículo científico publicado en 2015

DNA repair in diffuse large B-cell lymphoma: a molecular portrait

artículo científico publicado en 2014

Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

artículo científico publicado en 2009

Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.

artículo científico publicado en 2016

Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies

scientific article published on 01 August 2005

EZH2 in normal hematopoiesis and hematological malignancies

artículo científico publicado en 2016

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy

scientific article published on 01 October 2000

Evaluation of a peptide ELISA for the detection of rituximab in serum.

artículo científico publicado en 2007

Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies

artículo científico publicado en 2008

Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia

artículo científico publicado en 2015

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

artículo científico publicado en 2021

FCGR3A polymorphism story: a new piece of the puzzle

artículo científico publicado en 2009

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

artículo científico publicado en 2015

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

artículo científico publicado en 2016

Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?

artículo científico publicado en 2010

Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood

artículo científico publicado en 2002

From the bench to the bedside: ways to improve rituximab efficacy.

artículo científico publicado en 2004

Gota et al. on their article "the pharmacokinetics of Reditux™, a biosimilar of rituximab".

artículo científico publicado en 2016

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA

scientific article published on 01 March 2019

High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma ⬇️

artículo científico publicado el 1 de septiembre de 2010

Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production

artículo científico publicado en 2015

Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers

artículo científico publicado en 2015

Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients

artículo científico publicado en 2016

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

artículo científico publicado en 2011

Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients

artículo científico publicado en 2012

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

artículo científico publicado en 2016

Kinetic and organization of granulocytes transfusion: a case report

artículo científico publicado en 2014

Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks

artículo científico publicado en 2010

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

artículo científico publicado en 2013

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

artículo científico publicado en 2017

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

scientific article published on 11 December 2019

Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.

artículo científico publicado en 2003

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

artículo científico publicado en 2012

Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment

scientific article published on 11 April 2008

New anti-CD20 monoclonal antibodies: which is the best?

artículo científico publicado en 2014

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

artículo científico publicado en 2013

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

artículo científico publicado en 2014

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

artículo científico publicado en 2013

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

artículo científico publicado en 2013

Obinutuzumab in hematologic malignancies: lessons learned to date

artículo científico publicado en 2015

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

artículo científico publicado en 2018

Obinutuzumab: a new class of anti-CD20 monoclonal antibody.

artículo científico publicado en 2014

Obinutuzumab: what is there to learn from clinical trials?

artículo científico

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

artículo científico publicado en 2012

Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study

scientific article published on 20 April 2011

Pharmacokinetics of rituximab and its clinical use: thought for the best use?

artículo científico publicado en 2007

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

artículo científico publicado en 2012

Quantitative and qualitative analysis of the human primitive progenitor cell compartment after autologous stem cell transplantation.

artículo científico publicado en 2002

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2015

Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.

artículo científico publicado en 2007

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.

artículo científico publicado en 2016

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial

artículo científico publicado en 2012

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

artículo científico publicado en 2017

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

artículo científico publicado en 2016

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

scientific article published on 04 July 2018

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report

artículo científico publicado en 2017

Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines

artículo científico publicado en 2004

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

artículo científico publicado en 2018

Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.

artículo científico publicado en 2017

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

artículo científico publicado en 2004

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism

artículo científico publicado en 2015

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells

artículo científico publicado en 2016

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

artículo científico publicado en 2002

Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients

artículo científico publicado en 2016

Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines

artículo científico publicado en 2010

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

artículo científico publicado en 2008

Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure

scientific article published on 01 July 2003

[Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies]

artículo científico publicado en 2010

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study

artículo científico publicado en 2017

Lista de obras de Guillaume Cartron

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma

Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study

CD45 Isoform Profile Identifies Natural Killer (NK) Subsets with Differential Activity.

CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia.

Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis

Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group.

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

Clinical radioimmunotherapy--the role of radiobiology.

Comparison of EBV DNA viral load in whole blood, plasma, B-cells and B-cell culture supernatant

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

DNA repair in diffuse large B-cell lymphoma: a molecular portrait

Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.

Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies

EZH2 in normal hematopoiesis and hematological malignancies

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy

Evaluation of a peptide ELISA for the detection of rituximab in serum.

Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies

Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

FCGR3A polymorphism story: a new piece of the puzzle

Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma

First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.

Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?

Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy: a comparison with steady-state bone marrow and peripheral blood

From the bench to the bedside: ways to improve rituximab efficacy.

Gota et al. on their article "the pharmacokinetics of Reditux™, a biosimilar of rituximab".

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA

High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma ⬇️

Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production

Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers

Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients

Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.

Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Kinetic and organization of granulocytes transfusion: a case report

Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)

Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.

Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment

New anti-CD20 monoclonal antibodies: which is the best?

Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.

Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).

Obinutuzumab in hematologic malignancies: lessons learned to date

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Obinutuzumab: a new class of anti-CD20 monoclonal antibody.

Obinutuzumab: what is there to learn from clinical trials?

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study

Pharmacokinetics of rituximab and its clinical use: thought for the best use?

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

Quantitative and qualitative analysis of the human primitive progenitor cell compartment after autologous stem cell transplantation.

Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.

Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups.

Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report

Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

Treatment Response and Outcomes in Post-transplantation Lymphoproliferative Disease vs Lymphoma in Immunocompetent Patients

Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.